PRE Key Statistics, Chart & Performance
The current stock price of PRE is 16.75 USD. In the past month the price increased by 19.34%. In the past year, price increased by 208.47%.
PRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.77 | 102.32B | ||
| CI | THE CIGNA GROUP | 9.99 | 75.84B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 129.13 | 23.75B | ||
| LH | LABCORP HOLDINGS INC | 16.1 | 21.11B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.21 | 19.77B | ||
| GH | GUARDANT HEALTH INC | N/A | 14.01B | ||
| HIMS | HIMS & HERS HEALTH INC | 62.72 | 7.71B | ||
| DVA | DAVITA INC | 12.2 | 7.95B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 38.33 | 7.05B | ||
| CHE | CHEMED CORP | 20.42 | 6.36B | ||
| RDNT | RADNET INC | 206.26 | 6.05B | ||
| OPCH | OPTION CARE HEALTH INC | 21.45 | 5.07B |
Related stock screener links
About PRE
Company Profile
Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The company employs 285 full-time employees The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.
Company Info
PRENETICS GLOBAL LTD-CL A
Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
Hong Kong HM 08 HK
CEO: David Zwiener
Employees: 285
Phone: 85222109588
PRENETICS GLOBAL LTD-CL A / PRE FAQ
What does PRENETICS GLOBAL LTD-CL A do?
Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The company employs 285 full-time employees The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.
What is the current price of PRE stock?
The current stock price of PRE is 16.75 USD. The price increased by 1.58% in the last trading session.
What is the dividend status of PRENETICS GLOBAL LTD-CL A?
PRE does not pay a dividend.
How is the ChartMill rating for PRENETICS GLOBAL LTD-CL A?
PRE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the market cap for PRENETICS GLOBAL LTD-CL A?
PRENETICS GLOBAL LTD-CL A (PRE) has a market capitalization of 236.34M USD. This makes PRE a Micro Cap stock.
What is the outstanding short interest for PRENETICS GLOBAL LTD-CL A?
The outstanding short interest for PRENETICS GLOBAL LTD-CL A (PRE) is 0.6% of its float.
PRE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PRE. When comparing the yearly performance of all stocks, PRE is one of the better performing stocks in the market, outperforming 97.72% of all stocks.
PRE Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PRE Forecast & Estimates
5 analysts have analysed PRE and the average price target is 31.62 USD. This implies a price increase of 88.78% is expected in the next year compared to the current price of 16.75.